To summarize, CCAT2 was at a high level in BC tissues and cells, and CCAT2 may reduce chemosensitivity to 5‐Fu in BC cells by activating the mTOR pathway, manifesting CCAT2 may be a potential biomarker and therapeutic target for BC patients. This evidence concerns the gene CCAT2 and breast cancer.